Clinical Trial

Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

Name: Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM — clinical trial record (NCT07570810)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This is an exploratory study evaluating CS0159 in combination with Semaglutide in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with obesity and type 2 diabetes (T2DM).

Trial Details

NCT Number	NCT07570810
Lead Sponsor	Shanghai Jiao Tong University School of Medicine
Conditions	Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease
Enrollment	30 participants
Start Date	2026-06-01
Primary Completion	2026-11-30 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-06